China wants to have another round of talks with the U.S. before signing phase one of a trade deal, a source tells CNBC's Kayla Tausche.Marketsread more
"But I expect we'll have a deal," Mnuchin tells CNBC.Politicsread more
Wall Street analysts were largely skeptical of Trump's announcement on Friday of a substantial trade deal.Marketsread more
Apple will release the iPhone SE2 early next year for $399, analyst Ming-Chi Kuo says.Technologyread more
Sanders, who is recovering from a heart attack, reveals the new tax plan a day before the third Democratic debate.2020 Electionsread more
The Treasury secretary expresses optimism that the U.S. and China have a workable first-phase agreement.Economyread more
The ITB, the homebuilder's ETF, has its highest level since January 2018. Craig Johnson, chief market technician at Piper Jaffray, thinks there could be even more room to run.Trading Nationread more
However, that doesn't mean it won't cause harm, says Gottlieb. "You can't inhale something into the lungs on a repeated basis and not cause some damage to the lung."Health and Scienceread more
Climate change activists targeted BlackRock, the world's biggest asset manager, in London on Monday, demanding that the world's major financial institutions stop funding what...Environmentread more
The Salesforce CEO called for the establishment of a "new capitalism" that's partly funded by taxing the rich.Technologyread more
Industrials are gearing up for big gains, says Piper Jaffray's Craig Johnson. Here's one way to play the breakout.Trading Nationread more
Generic drugmaker Teva Pharmaceutical Industries on Tuesday proposed buying Mylan for $40 billion, saying it was a better deal than the smaller rival's offer to buy Perrigo. The bid comes after weeks of speculation that Teva, the world's largest generic company, would make a bid for Mylan.
Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10, which it said was the last day of trading prior to the widespread speculation.
Analyst Gilad Alper of the Excellence Nessuah brokerage in Petach Tikva near Tel Aviv said a Teva-Mylan combination would create a very large company that lacks assets to drive short-term growth.
Alper said he thought Teva would probably increase its $82-per-share offer and described Mylan's stock reaction as lackluster. "I would have thought the price would have jumped a little higher,'' he said.
Mylan was not immediately available for comment, but has said it is not interested in a deal. Executive Chairman Robert Coury said in a statement on Friday that Mylan was committed to the $29 billion offer it made earlier this month for Perrigo.
In a letter to Coury, Teva Chief Executive Officer Erez Vigodman urged the company to meet to address the concerns it has voiced about a combination, such as doubts that it would pass antitrust review. Vigodman said Teva believed the combination would gain regulatory clearance.
Read MoreTeva to buy Auspex in all-cash deal
Mylan has adopted a poison pill defense, a shareholder rights plan that makes a hostile takeover less likely because it triggers the sale of discounted stock that dilutes share value.
Perrigo has not commented on the deal since April 8, when it said it would take the Mylan offer to its board.
The combined company would have annual revenue of $30 billion, and Teva said it would expect $2 billion in cost savings within three years, including from taxes.
Teva is based in Israel while Mylan recently moved its headquarters from the United States to the Netherlands, where corporate taxes are lower.
Teva said Mylan would add to its earnings starting in the first year.
Teva is being advised by Barclays and Greenhill, and its lawyers are Kirkland & Ellis, Tulchinsky Stern Marciano Cohen Levitski, De Brauw Blackstone Westbroek, and Loyens & Loeff.